Hengrui Pharma(SH:600276) Xin Lang Zheng Quan·2025-12-19 02:27Core Insights - Heng Rui Medicine's stock price increased by 2.00% on December 19, reaching 61.20 CNY per share, with a total market capitalization of 406.197 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.92%, but a decline of 3.29% in the last five trading days [1] Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2] - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, with applications across various diseases [2] - Main business revenue composition: 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2] Financial Performance - As of September 30, Heng Rui Medicine reported a revenue of 23.188 billion CNY for the first nine months of 2025, a year-on-year increase of 14.85% [3] - The net profit attributable to shareholders for the same period was 5.751 billion CNY, reflecting a year-on-year growth of 24.50% [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 397,300, with an average of 16,058 circulating shares per person [3] - The company has distributed a total of 9.303 billion CNY in dividends since its A-share listing, with 3.568 billion CNY in the last three years [4] - Major shareholders include Hong Kong Central Clearing Limited and China Securities Finance Corporation, with some reductions in shareholdings noted [4]